Business
Amarantus Announces Peer-Reviewed Publication Further Describing Mechanisms of Action for Eltoprazine in the Treatment of Parkinson's LID
Amarantus Announces Peer-Reviewed Publication Further Describing Mechanisms of Action for Eltoprazine in the Treatment of Parkinson's LID.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus Announces Peer-Reviewed Publication Further Describing Mechanisms of Action for Eltoprazine in the Treatment of Parkinson's LID\n\n\n\n\n\nAmarantus Announces Peer-Reviewed Publication Further Describing Mechanisms of Action for Eltoprazine in the Treatment of Parkinson's LID\nPR Newswire\nSAN FRANCISCO, December 16, 2015\n\n\n\nSAN FRANCISCO, December 16, 2015 /PRNewswire/ --\n\nAmarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced the publication of a new independent peer-reviewed publication describing the mechanisms by which eltoprazine may act to overcome Parkinson's Disease levodopa-induced dyskinesia (PD-LID). The paper, entitled \"Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms\" by V. Ghiglieri, et al., was published in the journal Neurobiology of Disease.\n\nHighlights from the publication include:\n\n\nThe serotonergic pathway in the brain has a relevant role in PD-LID, a significantly disabling locomotor-related consequence of L-DOPA treatment;\n\nEltoprazine, a serotonin receptor agonist, reduces these locomotor disturbances and restores striatal bidirectional synaptic plasticity in the brain;\n\nOn a molecular level, eltoprazine normalizes functionality of two key signaling pathways (D1R-dependent cAMP/PKA and ERK/mTORC pathways);\n\nThe locomotor defect in parkinsonian and L-DOPA-treated rats is reversed by eltoprazine treatment.\n\n\nEltoprazine, is a clinical Phase 2b stage small molecule targeted for the treatment of PD-LID. Enrollment for the current study is temporarily paused as the company awaits a decision from the US Food & Drug Administration on an orphan drug application submitted by Amarantus for the treatment of PD-LID that may alter the Company's development strategy. PD-LID is an abnormal, involuntary  movement disorder resulting from prolonged levodopa-based therapy, the most commonly prescribed treatment for Parkinson's disease. PD-LID is one of the most difficult problems facing people with the disease. Dyskinesia can be severely disabling and can impact quality of life by prohibiting the ability to perform routine daily functions.\n\n\"This publication strengthens our ...